Tissue engineering small-diameter vascular grafts: Preparation of a biocompatible porcine ureteric scaffold

Tissue Engineering - Part A.

Volumn 14, Issue 11, 2008, Pages 1871-1882

  Derham, Chris ^a,b   Yow, Heng ^a   Ingram, Joanne ^a   Fisher, John ^a   Ingham, Eileen ^a   Korrosis, Sotirios A ^a   Homer Vanniasinkam, Shervanthi ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDS; BIOCHEMISTRY; BIOCOMPATIBILITY; BIOMECHANICS; CELL CULTURE; ENDOTHELIAL CELLS; GRAFTS; HISTOLOGY; MACROPHAGES; MUSCLE; PROTEINS; SODIUM; TISSUE; TISSUE ENGINEERING;

BASEMENT MEMBRANES; BIOCOMPATIBLE; BIOMECHANICAL PROPERTIES; BURST PRESSURES; CYTOTOXICITY TESTS; DECELLULARIZED; DECELLULARIZED SCAFFOLDS; FIBROUS TISSUES; FRESH TISSUES; HUMAN SAPHENOUS VEINS; IMMUNOCYTOCHEMISTRY; IN VITRO; IN-VIVO; INFLAMMATORY CELLS; MOUSE MODELS; PERACETIC ACIDS; PROTEINASE INHIBITORS; QUANTITATIVE DETERMINATIONS; REPAIR PROCESSES; SEQUENTIAL TREATMENTS; SMOOTH MUSCLE ACTINS; SMOOTH MUSCLES; SODIUM DODECYL SULPHATE; SUBCUTANEOUS IMPLANTATIONS; TRIS BUFFERS; ULTIMATE TENSILE STRENGTHS; VASCULAR GRAFTS;

SCAFFOLDS;

ALPHA GALACTOSIDASE; ALPHA GALACTOSYLCERAMIDE; ALPHA SMOOTH MUSCLE ACTIN; BIOMATERIAL; BLOOD CLOTTING FACTOR 8; CD3 ANTIBODY; DEOXYRIBONUCLEASE; DODECYL SULFATE SODIUM; EPITOPE; GALACTOSE; MEMBRANE PROTEIN; NUCLEASE; PERACETIC ACID; PROTEINASE INHIBITOR; RIBONUCLEASE; SULFATE; TROMETAMOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BIOCHEMISTRY; BIOCOMPATIBILITY; BIOMECHANICS; BLOOD VESSEL DIAMETER; BLOOD VESSEL GRAFT; CELL FUNCTION; CELL INFILTRATION; COMPLIANCE (PHYSICAL); CONTROLLED STUDY; CYTOTOXICITY TEST; ENDOTHELIUM CELL; EXPLANT; FEMALE; FIBROBLAST; HISTOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; KIDNEY FAILURE; MACROPHAGE; MOUSE; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; SWINE; TENSILE STRENGTH; TISSUE ENGINEERING; TISSUE REPAIR; TISSUE STRUCTURE; URETER;

MUS; SUS;

EID: 54949089305     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2007.0103     Document Type: Article

References (33)

1. Dardik H, Miller N, Dardik A, Ibrahim I, Sussman B, Berry SM, et al. A decade of experience with the glutaraldehyde-tanned human umbilical cord vein graft for revascularization of the lower limb. J Vasc Surg 7, 336, 1988.
2. Dardik H, Wengerter K, Qin F, Pangilinan A, Silvestri F, Wolodiger F, et al. Comparative decades of experience with glutaraldehyde-tanned human umbilical cord vein graft for lower limb revascularization: an analysis of 1275 cases. J Vasc Surg 35, 64, 2002.
3. Clarke DR, Lust RM, Sun YS, Black KS, Ollerenshaw JD. Transformation of nonvascular acellular tissue matrices into durable vascular conduits. Ann Thorac Surg 71(5 Suppl), S433, 2001.
4. Field PL. The chemically treated bovine ureter - clinical performance of a novel biological vascular prosthesis. Cardiovasc Surg 11, 30, 2003.
5. Widmer MK, Aregger F, Stauffer E, Savolainen H, Heller G, Hakki H, et al. Intermediate outcome and risk factor assessment of bovine vascular heterografts used as AV-fistulas for hemodialysis access. Eur J Vasc Endovasc Surg 27, 660, 2004.
6. Madden R, Lipkowitz G, Benedetto B, Kurbanov A, Miller M, Bow L. Decellularized cadaver vein allografts used for hemodialysis access do not cause allosensitization or preclude kidney transplantation. Am J Kidney Dis 40, 1240, 2002.
7. Schaner PJ, Martin ND, Tulenko TN, Shapiro IM, Tarola NA, Leichter RF, et al. Decellularized vein as a potential scaffold for vascular tissue engineering. J Vasc Surg 40, 146, 2004.
8. Madden RL, Lipkowitz GS, Browne BJ, Kurbanov A. A comparison of cryopreserved vein allografts and prosthetic grafts for hemodialysis access. Ann Vasc Surg 19, 686, 2005.
9. Niklason LE, Abbott W, Gao J, Klagges B, Hirschi KK, Ulubayram K, et al. Morphologic and mechanical characteristics of engineered bovine arteries. J Vasc Surg 33, 628, 2001.
10. Yelluri S, Derham C, Wong Y, Leitch J, Spark J. Incomplete cellular depopulation may explain the high failure rate of the bovine ureteric graft. Br J Surg 95, 582, 2008.
11. Weinberg CB, Bell E. A blood vessel model constructed from collagen and cultured vascular cells. Science 231, 397, 1986.
12. Berglund JD, Mohseni MM, Nerem RM, Sambanis A. A biological hybrid model for collagen-based tissue engineered vascular constructs. Biomaterials 24, 1241, 2003.
13. L'Heureux N, Paquet S, Labbe R, Germain L, Auger FA. A completely biological tissue-engineered human blood vessel. FASEB J 12, 47, 1998.
14. Tiwari A, Salacinski H, Seifalian AM, Hamilton G. New prostheses for use in bypass grafts with special emphasis on polyurethanes. Cardiovasc Surg 10, 191, 2002.
15. Niklason LE, Gao J, Abbott WM, Hirschi KK, Houser S, Marini R, et al. Functional arteries grown in vitro. Science 284, 489, 1999.
16. Auger FA, Rouabhia M, Goulet F, Berthod F, Moulin V, Germain L. Tissue-engineered human skin substitutes developed from collagen-populated hydrated gels: clinical and fundamental applications. Med Biol Eng Comput 36, 801, 1998.
17. L'Heureux N, Dusserre N, Konig G, Victor B, Keire P, Wight TN, et al. Human tissue-engineered blood vessels for adult arterial revascularization. Nat Med 12, 361, 2006.
18. Matsuura JH, Black KS, Levitt AB, Rosenthal D, Wellons ED, Fallon MT, et al. Cellular remodeling of depopulated bovine ureter used as an arteriovenous graft in the canine model. J Am Coll Surg 198, 778, 2004.
19. Booth C, Korossis SA, Wilcox HE, Watterson KG, Kearney JN, Fisher J, et al. Tissue engineering of cardiac valve prostheses I: development and histological characterization of an acellular porcine scaffold. J Heart Valve Dis 11, 457, 2002.
20. Wilshaw SP, Kearney JN, Fisher J, Ingham E. Production of an acellular amniotic membrane matrix for use in tissue engineering. Tissue Eng 12, 2117, 2006.
21. Edwards CA, O'Brien WD, Jr. Modified assay for determination of hydroxyproline in a tissue hydrolyzate. Clin Chim Acta 104, 161, 1980.
22. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 883, 173, 1986.
23. Korossis SA, Booth C, Wilcox HE, Watterson KG, Kearney JN, Fisher J, et al. Tissue engineering of cardiac valve prostheses II: biomechanical characterization of decellularized porcine aortic heart valves. J Heart Valve Dis 11, 463, 2002.
24. Korossis SA, Wilcox HE, Watterson KG, Kearney JN, Ingham E, Fisher J. In-vitro assessment of the functional performance of the decellularized intact porcine aortic root. J Heart Valve Dis 14, 408, 2005.
25. Bolland F, Korossis S, Wilshaw SP, Ingham E, Fisher J, Kearney JN, et al. Development and characterisation of a full-thickness acellular porcine bladder matrix for tissue engineering. Biomaterials 28, 1061, 2007.
26. Badylak SF. Xenogeneic extracellular matrix as a scaffold for tissue reconstruction. Transpl Immunol 12, 367, 2004.
27. Jernigan TW, Croce MA, Cagiannos C, Shell DH, Handorf CR, Fabian TC. Small intestinal submucosa for vascular reconstruction in the presence of gastrointestinal contamination. Ann Surg 239, 733, 2004.
28. Sandrin MS, McKenzie IF. Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev 141, 169, 1994.
29. Harding JJ, Wesley JM. The purification and amino acid composition of human uterus collagens, rheumatoid-arthritis-nodule collagen and ox tendon collagen. Biochem J 106, 749, 1968.
30. Knudsen L, Gregersen H, Eika B, Frokiaer J. Elastic wall properties and collagen content in the ureter: an experimental study in pigs. Neurourol Urodyn 13, 597, 1994.
31. Sarkar S, Hillery C, Seifalian A, Hamilton G. Critical parameter of burst pressure measurement in development of bypass grafts is highly dependent on methodology used. J Vasc Surg 44, 846, 2006.
32. Bodnar E, Olsen EG, Florio R, Dobrin J. Damage of porcine aortic valve tissue caused by the surfactant sodiumdodecylsulphate. Thorac Cardiovasc Surg 34, 82, 1986.
33. Badylak SF, Valentin J, Stewart-Akers A. In vivo remodelling of ECM scaffolds as a function of macrophage phenotype. Presented at Termis Meeting, 2007, Toronto, Canada.